Can Smithkline Keep Flying Solo?

Many investors hope that the Glaxo deal can be revived

Jan Leschly is under fire. The chief executive of SmithKline Beecham PLC watched his company's stock slide 31% between late February and early October, after merger talks with rival Glaxo Wellcome PLC collapsed. Worse, in the last two weeks, the shares have spiked back up on rumors--which Leschly hotly denies--that he will retire early.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.